CGTX Stock Price, Cognition Therapeutics, . Quote, Chart

Market Summary

USD1.98+0.04

Delayed

2.06%

CGTX Stock Price

View Fullscreen

CGTX RSI Chart

CGTX Valuation

Market Cap

79.3M

Price/Earnings (Trailing)

-2.76

Price/Sales (Trailing)

3.48

EV/EBITDA

-2.07

Price/Free Cashflow

-3.83

CGTX Price/Sales (Trailing)

CGTX Profitability

EBT Margin

-89.89%

Return on Equity

-99.68%

Return on Assets

-74.04%

Free Cashflow Yield

-26.1%

CGTX Fundamentals

CGTX Revenue

Revenue (TTM)

22.8M

Rev. Growth (Yr)

43.37%

Rev. Growth (Qtr)

-27.44%

CGTX Earnings

Earnings (TTM)

-28.8M

Earnings Growth (Yr)

-48.27%

Earnings Growth (Qtr)

-12.41%

Breaking Down CGTX Revenue

Last 7 days

2.1%

Last 30 days

4.2%

Last 90 days

1.0%

Trailing 12 Months

-1%

How does CGTX drawdown profile look like?

CGTX Financial Health

Current Ratio

4

CGTX Investor Care

Shares Dilution (1Y)

36.82%

Diluted EPS (TTM)

-0.92

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	22.8M	0	0	0
2023	19.7M	0	21.0M	21.9M
2022	18.7M	20.4M	23.3M	22.2M
2021	12.5M	14.2M	15.8M	17.4M
2020	0	0	0	10.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cognition Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 01, 2024	doyle john brendan	sold (taxes)	-16,963	1.95	-8,699	chief financial officer
Mar 14, 2024	ricciardi lisa	bought	9,975	1.75	5,700	ceo & president
Feb 15, 2024	ricciardi lisa	acquired	-	-	75,000	ceo & president
Feb 15, 2024	doyle john brendan	acquired	-	-	20,000	chief financial officer
Feb 15, 2024	caggiano anthony	acquired	-	-	60,000	chief medical officer
Feb 03, 2024	caggiano anthony	sold (taxes)	-29,259	2.29	-12,777	chief medical officer
Feb 03, 2024	ricciardi lisa	sold (taxes)	-63,726	2.29	-27,828	ceo & president
Nov 08, 2023	kreis leslie w.	acquired	525,100	1.05	500,095	-
Nov 08, 2023	fletcher aaron g.l.	acquired	525,100	1.05	500,095	-
Jun 09, 2023	monia brett p	acquired	-	-	6,000	-

Which funds bought or sold CGTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	LEVIN CAPITAL STRATEGIES, L.P.	new	-	54,600	54,600	-%
May 16, 2024	AWM Investment Company, Inc.	new	-	1,183,000	1,183,000	0.16%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-0.28	-176	9,100	-%
May 15, 2024	Kestra Advisory Services, LLC	reduced	-9.11	-42,983	362,970	-%
May 15, 2024	Northeast Financial Consultants Inc	unchanged	-	-735	44,590	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	31.87	2,677	11,681	-%
May 15, 2024	Alyeska Investment Group, L.P.	new	-	910,000	910,000	0.01%
May 15, 2024	CORSAIR CAPITAL MANAGEMENT, L.P.	new	-	518,700	518,700	0.15%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	unchanged	-	-176	10,678	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-15.9	-29,126	139,594	-%

Are Funds Buying or Selling CGTX?

Are funds buying CGTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CGTX

No. of Funds

Unveiling Cognition Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 07, 2024	hirschman orin	4.8%	1,448,270	SC 13G/A
Jan 19, 2024	pathstone family office, llc	7.53%	2,205,377	SC 13G
Nov 13, 2023	bios memory spv i, lp	4.6%	1,424,014	SC 13D/A
Feb 15, 2023	hirschman orin	7.0%	2,037,853	SC 13G/A
Dec 05, 2022	bios memory spv i, lp	5.9%	1,424,014	SC 13D/A
Nov 18, 2022	hirschman orin	7.0%	2,037,853	SC 13G

Recent SEC filings of Cognition Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
May 03, 2024	4	Insider Trading
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Mar 26, 2024	10-K	Annual Report
Mar 26, 2024	8-K	Current Report
Mar 26, 2024	S-8	Employee Benefits Plan
Mar 14, 2024	4	Insider Trading

Peers (Alternatives to Cognition Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.57	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Cognition Therapeutics, Inc. News

Latest updates

Cognition Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Revenue	-27.4%	4,912,000	6,770,000	7,684,000	3,426,000	3,981,000	5,947,000	6,385,000	5,904,000	5,072,000	3,037,000	4,646,000	4,692,000	3,942,000	3,192,000
Operating Expenses	-7.2%	14,102,000	15,189,000	14,745,000	8,973,000	9,300,000	12,625,000	12,213,000	9,413,000	11,808,000	5,223,000	5,984,000	5,583,000	-	4,461,000
S&GA Expenses	-100.0%	-	3,589,000	3,076,000	3,543,000	2,860,000	4,357,000	3,115,000	2,895,000	6,235,000	1,548,000	1,090,000	1,153,000	-	1,062,000
R&D Expenses	-9.0%	10,553,000	11,600,000	11,669,000	5,430,000	6,440,000	8,268,000	9,098,000	6,518,000	5,573,000	3,675,000	4,894,000	4,430,000	-	3,399,000
EBITDA Margin	4.1%	-0.90	-0.93	-0.97	-0.87	-0.49	-0.46	-0.53	-	-	-	-	-	-	-
Interest Expenses	-11.1%	-10,000	-9,000	-2,000	-10,000	-10,000	-2,000	-7,000	-9,000	1,000	-	-357,000	-537,000	-	-506,000
Income Taxes	-	-	-	-	-	-	-	-125,000	125,000	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-6,172,000	-	-	-5,877,000	-3,713,000	-	-	-1,490,000	223,000	-	-
EBT Margin	4.1%	-0.90	-0.94	-0.97	-0.87	-0.49	-0.47	-0.53	-	-	-	-	-	-	-
Net Income	-12.4%	-9,151,000	-8,141,000	-6,749,000	-6,172,000	-5,182,000	-6,625,000	-5,752,000	-3,838,000	-7,339,000	-3,110,000	-1,490,000	223,000	-1,868,000	-1,791,000
Net Income Margin	-7.0%	-1.26	-1.18	-1.09	-1.20	-0.96	-1.01	-0.98	-0.85	-0.67	-0.40	-0.35	-0.41	-0.72	-
Free Cashflow	-32.6%	-7,274,000	-5,486,000	-4,219,000	-2,746,000	-10,194,000	-27,000	-5,361,000	-3,122,000	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	10.5%	39.00	35.00	39.00	44.00	46.00	50.00	54.00	53.00	59.00	59.00	13.00	7.00
Current Assets	10.9%	38.00	34.00	36.00	42.00	43.00	48.00	51.00	51.00	56.00	59.00	10.00	7.00
Cash Equivalents	15.9%	35.00	30.00	33.00	37.00	39.00	42.00	47.00	46.00	52.00	55.00	8.00	5.00
Net PPE	-9.5%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-6.5%	10.00	11.00	10.00	10.00	10.00	10.00	14.00	9.00	10.00	8.00	15.00	20.00
Current Liabilities	-6.5%	10.00	10.00	8.00	8.00	7.00	8.00	12.00	7.00	8.00	8.00	4.00	3.00
Shareholder's Equity	17.9%	29.00	24.00	29.00	34.00	36.00	40.00	39.00	44.00	49.00	51.00	-	-
Retained Earnings	-6.5%	-150	-141	-133	-126	-121	-115	-110	-103	-97.84	-94.00	-86.66	-68.22
Additional Paid-In Capital	8.0%	179	166	162	161	158	156	150	148	147	145	0.00	0.00
Shares Outstanding	21.2%	39.00	32.00	30.00	30.00	29.00	29.00	23.00	23.00	22.00	22.00	-	1.00
Float	-	-	-	-	43.00	-	-	-	38.00	-	81.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	-32.8%	-7,244	-5,456	-4,161	-3,696	-2,705	-10,184	-4.00	-5,357	-2,988	101	-2,050	-910	-772	-	-
Share Based Compensation	9.3%	1,171	1,071	1,071	1,025	1,187	902	777	892	1,001	4,919	72.00	94.00	98.00	-	-
Cashflow From Investing	100.0%	-	-30.00	-58.00	-18.00	-41.00	-10.00	-23.00	-4.00	-134	-	-	-	-	-	-
Cashflow From Financing	391.7%	11,993	2,439	-3.00	2,095	-10.00	5,142	869	-374	-91.00	46,361	-961	-1,155	8,956	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CGTX Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating Expenses:
Research and development	$ 10,553	$ 5,430
General and administrative	3,549	3,543
Total operating expenses	14,102	8,973
Loss from operations	(14,102)	(8,973)
Other income (expense):
Grant income	4,912	3,426
Other income (expense), net	244	(615)
Interest expense	(10)	(10)
Loss on currency translation from liquidation of subsidiary	(195)
Total other income, net	4,951	2,801
Net loss	(9,151)	(6,172)
Foreign currency translation adjustment, including reclassifications	195	4
Total comprehensive loss	$ (8,956)	$ (6,168)
Net loss per share, basic (in dollars per share)	$ (0.27)	$ (0.21)
Net loss per share, diluted (in dollars per share)	$ (0.27)	$ (0.21)
Weighted-average common shares outstanding, basic (in shares)	33,735,269	29,094,592
Weighted-average common shares outstanding, diluted (in shares)	33,735,269	29,094,592

CGTX Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 34,671	$ 29,922
Grant receivables	861	1,281
Prepaid expenses and other current assets	2,436	3,019
Total current assets	37,968	34,222
Property and equipment, net	257	284
Right-of-use assets, operating leases	626	657
Total assets	38,851	35,163
Current liabilities:
Accounts payable	2,639	3,695
Accrued expenses	4,734	4,055
Deferred grant income, current	1,584	1,701
Operating lease liabilities, current	180	174
Other current liabilities	366	544
Total current liabilities	9,503	10,169
Operating lease liabilities, noncurrent	488	520
Deferred grant income and other liabilities, noncurrent	0	0
Total liabilities	9,991	10,689
Commitments and contingencies (Note 6)
Stockholders' equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.001 par value, 250,000,000 shares authorized; 39,985,866 and 32,165,478 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	40	32
Additional paid-in capital	179,160	165,826
Accumulated deficit	(150,340)	(141,189)
Accumulated other comprehensive loss		(195)
Total stockholders' equity	28,860	24,474
Total liabilities and stockholders' equity	$ 38,851	$ 35,163

About Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.

CEO	Ms. Lisa Ricciardi
WEBSITE	cogrx.com
INDUSTRY	Biotechnology
EMPLOYEES	22

Cognition Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Cognition Therapeutics, Inc.? What does CGTX stand for in stocks?

CGTX is the stock ticker symbol of Cognition Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cognition Therapeutics, Inc. (CGTX)?

As of Fri May 17 2024, market cap of Cognition Therapeutics, Inc. is 79.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CGTX stock?

You can check CGTX's fair value in chart for subscribers.

What is the fair value of CGTX stock?

You can check CGTX's fair value in chart for subscribers. The fair value of Cognition Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cognition Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CGTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cognition Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether CGTX is over valued or under valued. Whether Cognition Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Cognition Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CGTX.

What is Cognition Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CGTX's PE ratio (Price to Earnings) is -2.76 and Price to Sales (PS) ratio is 3.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CGTX PE ratio will change depending on the future growth rate expectations of investors.